Biosergen
A Swedish, clinical-stage biotechnology company developing antifungal drugs.
The company's lead drug candidate is BSG005, a potentially disruptive antifungal drug, which has demonstrated significant safety and potency advantages over competing antifungals.
Latest Biosergen News & Features
27 September 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze